Literature DB >> 33777430

Complications and Management of Totally Implantable Central Venous Access Ports in Cancer Patients at a University Hospital in Oman.

Philomena C D'Souza1, Shiyam Kumar2, Annupam Kakaria3, Rashid Al-Sukaiti3, Khalid Al-Baimani3, Rana S Hamid3, Alok K Mittal3, Muna Al-Balushi4, Ikram A Burney5, Mansour S Al-Moundhri5.   

Abstract

OBJECTIVES: Totally implantable central venous access ports (port-a-caths) are increasingly used for the safe administration of chemotherapy; however, their use is associated with complications. This study reviews patterns of complications, reasons for premature removal and the duration of the use of port-a-caths in patients receiving cancer treatment at Sultan Qaboos University Hospital (SQUH) and compares the infection rate with the literature and the researchers' experiences.
METHODS: This retrospective follow-up study included patients who had received cancer treatment through a port-a-cath and were admitted to SQUH between January 2007 and April 2019. Demographic features, underlying diagnosis, clinical stage, treatment, duration of use and the cause of premature removal of the port-a-cath were recorded.
RESULTS: A total of 516 port-a-caths were inserted in 482 cancer patients. The majority of devices were implanted by interventional radiologists (n = 459; 89.0%) and the right internal jugular vein was most frequently accessed (n = 396; 76.7%). The mean indwelling time of a port-a-cath was 288 days (range: 3-1,872 days) for patients with complications and 550 days (range: 7-3,123 days) for patients without complications. Port-a-cath-related infection was the main complication (n = 63; 12.2%). Patient age, gender, treatment intent, underlying diagnosis, clinical stage, chemotherapy regimen, number of treatment courses, operator implanting the port, the type of micro-organism isolated from the port-a-cath and body mass index were significant factors affecting catheter indwelling time (P <0.05). On multivariate analysis, however, none of the factors was found to be significant.
CONCLUSION: Infection was the most common complication necessitating port-a-cath removal. The infection rate was much lower than the researchers' previous experience and compares favorably with several published reports. © Copyright 2021, Sultan Qaboos University Medical Journal, All Rights Reserved.

Entities:  

Keywords:  Cancer; Catheter-Related Infections; Oman; Port-A-Cath; Vascular Access Ports

Mesh:

Substances:

Year:  2021        PMID: 33777430      PMCID: PMC7968907          DOI: 10.18295/squmj.2021.21.01.014

Source DB:  PubMed          Journal:  Sultan Qaboos Univ Med J        ISSN: 2075-051X


  26 in total

1.  Use of port-a-cath in cancer patients: a single-center experience.

Authors:  Philomena Charlotte D'Souza; Shiyam Kumar; Annupam Kakaria; Rashid Al-Sukaiti; Khawaja Farhan Zahid; Muhammad Furrukh; Ikram A Burney; Mansour S Al-Moundhri
Journal:  J Infect Dev Ctries       Date:  2014-11-13       Impact factor: 0.968

2.  Central venous access in oncology: ESMO Clinical Practice Guidelines.

Authors:  B Sousa; J Furlanetto; M Hutka; P Gouveia; R Wuerstlein; J M Mariz; D Pinto; F Cardoso
Journal:  Ann Oncol       Date:  2015-09       Impact factor: 32.976

3.  Totally implantable central venous access ports. Analysis of 700 cases.

Authors:  Nikolaos Barbetakis; Christos Asteriou; Athanassios Kleontas; Christodoulos Tsilikas
Journal:  J Surg Oncol       Date:  2011-06-13       Impact factor: 3.454

4.  Follow-up of radiologically totally implanted central venous access ports of the upper arm: long-term complications in 127,750 catheter-days.

Authors:  Jasmin D Busch; Jochen Herrmann; Friederike Heller; Thorsten Derlin; Andreas Koops; Gerhard Adam; Christian R Habermann
Journal:  AJR Am J Roentgenol       Date:  2012-08       Impact factor: 3.959

5.  The late complications of totally implantable central venous access ports: the results from an Italian multicenter prospective observation study.

Authors:  Alberto Dal Molin; Laura Rasero; Linda Guerretta; Elisa Perfetti; Mario Clerico
Journal:  Eur J Oncol Nurs       Date:  2010-12-16       Impact factor: 2.398

6.  Complications and management of long-term central venous access catheters and ports.

Authors:  B Yildizeli; T Laçin; H F Batirel; M Yüksel
Journal:  J Vasc Access       Date:  2004 Oct-Dec       Impact factor: 2.283

7.  Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial.

Authors:  M Karthaus; A Kretzschmar; H Kröning; M Biakhov; D Irwin; N Marschner; C Slabber; G Fountzilas; A Garin; N G F Abecasis; W Baronius; G G Steger; T Südhoff; C Giorgetti; P Reichardt
Journal:  Ann Oncol       Date:  2005-11-29       Impact factor: 32.976

8.  Incidence and risk factors for central venous access port-related infection in Chinese cancer patients.

Authors:  Ting-Yao Wang; Kuan-Der Lee; Ping-Tsung Chen; Min-Chi Chen; Yi-Yang Chen; Cih-En Huang; Feng-Che Kuan; Chih-Cheng Chen; Chang Hsien Lu
Journal:  J Formos Med Assoc       Date:  2015-08-05       Impact factor: 3.282

Review 9.  Primary thromboprophylaxis for cancer patients with central venous catheters--a reappraisal of the evidence.

Authors:  M S Cunningham; B White; D Hollywood; J O'Donnell
Journal:  Br J Cancer       Date:  2006-01-30       Impact factor: 7.640

10.  Ultrasound and fluoroscopy-guided placement of central venous ports via internal jugular vein: retrospective analysis of 1254 port implantations at a single center.

Authors:  Se Jin Ahn; Hyo-Cheol Kim; Jin Wook Chung; Sang Bu An; Yong Hu Yin; Hwan Jun Jae; Jae Hyung Park
Journal:  Korean J Radiol       Date:  2012-04-17       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.